See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Social Media
Education
Senate
Taxes
Soccer
Tariffs
Artificial Intelligence
Donald Trump
Stock Markets
Republican Party
Published • loading... • Updated

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of ...

Summary by Hastings Tribune
Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression

3 Articles

All
Left
Center
1
Right
Hastings TribuneHastings Tribune
Center

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of ...

Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression

Read Full Article
European Medical JournalEuropean Medical Journal

Phase 2 trial begins for psychedelic-based depression treatment

The post Phase 2 trial begins for psychedelic-based depression treatment appeared first on European Medical Journal.

Read Full Article
pipelinereviewpipelinereview

Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity - Pipelinereview

BEIJING, China and BRIDGEWATER, NJ, USA I March 10, 2025 I Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a Phase 2 clinical trial of bofanglutide (research code: GZR18) injection, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) independently developed by Gan & Lee, in the US participants with overweight or obesity. Notably, bofanglutide i…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pipelinereview broke the news in on Tuesday, March 11, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal